Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Apellis Pharmaceuticals (APLS) Gross Margin (2021 - 2025)

Historic Gross Margin for Apellis Pharmaceuticals (APLS) over the last 5 years, with Q3 2025 value amounting to 94.65%.

  • Apellis Pharmaceuticals' Gross Margin rose 117000.0% to 94.65% in Q3 2025 from the same period last year, while for Sep 2025 it was 88.85%, marking a year-over-year increase of 23800.0%. This contributed to the annual value of 84.93% for FY2024, which is 3100.0% down from last year.
  • Latest data reveals that Apellis Pharmaceuticals reported Gross Margin of 94.65% as of Q3 2025, which was up 117000.0% from 92.37% recorded in Q2 2025.
  • In the past 5 years, Apellis Pharmaceuticals' Gross Margin ranged from a high of 99.92% in Q4 2021 and a low of 79.4% during Q1 2025
  • Its 5-year average for Gross Margin is 89.16%, with a median of 88.43% in 2024.
  • As far as peak fluctuations go, Apellis Pharmaceuticals' Gross Margin crashed by -140400bps in 2023, and later surged by 117000bps in 2025.
  • Over the past 5 years, Apellis Pharmaceuticals' Gross Margin (Quarter) stood at 99.92% in 2021, then decreased by -13bps to 87.09% in 2022, then dropped by -1bps to 86.4% in 2023, then dropped by -7bps to 80.78% in 2024, then increased by 17bps to 94.65% in 2025.
  • Its Gross Margin was 94.65% in Q3 2025, compared to 92.37% in Q2 2025 and 79.4% in Q1 2025.